Show simple item record

dc.contributor.authorHunter, B.
dc.contributor.authorCrockett, Cathryn
dc.contributor.authorFaivre-Finn, Corinne
dc.contributor.authorHiley, C.
dc.contributor.authorSalem, Ahmed
dc.date.accessioned2021-04-06T15:07:00Z
dc.date.available2021-04-06T15:07:00Z
dc.date.issued2021en
dc.identifier.citationHunter B, Crockett C, Faivre-Finn C, Hiley C, Salem A. Re-Irradiation of Recurrent Non-Small Cell Lung Cancer. Semin Radiat Oncol. 2021;31(2):124-32.en
dc.identifier.pmid33610269en
dc.identifier.doi10.1016/j.semradonc.2020.11.009en
dc.identifier.urihttp://hdl.handle.net/10541/623837
dc.description.abstractLocoregional recurrence occurs in 10%-30% of non-small cell lung cancer (NSCLC) after treatment with definitive (chemo)radiotherapy. Re-irradiation is the main curative-intent treatment option for these patients; however, it represents a therapeutic challenge for thoracic radiation oncologists. Re-irradiation practices are variable worldwide with lack of agreement on the optimal dose or the cumulative maximum dose acceptable for critical organs. The role of re-irradiation in NSCLC is also not clearly defined in the era of immunotherapy. In this review, we will present published and on-going re-irradiation studies for recurrent NSCLC. We will appraise available evidence for critical organ dose constraints and provide a framework for future therapeutic approaches and trialsen
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.semradonc.2020.11.009en
dc.titleRe-Irradiation of recurrent non-small cell lung icanceren
dc.typeArticleen
dc.contributor.departmentThe Royal Marsden Hospital, Chelsea, UKen
dc.identifier.journalSeminars in Radiation Oncologyen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record